Approved HIV Drugs
Approved HIV Drugs
IAS 2011: Raltegravir Still Effective at 5 Years
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 26 July 2011 00:00
- Written by Merck
The sole approved integrase inhibitor, raltegravir (Isentress), continues to keep HIV suppressed for nearly 5 years in patients starting treatment for the first time, according to astudy presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) last week in Rome.
Abacavir Looks as Safe and Effective as Tenofovir
- Details
- Category: Approved HIV Drugs
- Published on Friday, 15 July 2011 00:00
- Written by Liz Highleyman
A meta-analysis of 28 controlled trials did not find elevated heart attack risk with abacavir, and a Canadian study showed no greater risk of treatment failure among patients with high viral load, according to 2 recently published reports.
The association between use of abacavir (Ziagen, also in the Epzicom and Trizivir coformulations) and myocardial infarction (MI), or heart attack, remains controversial, as does the suggestion that abacavir may not work as well for people who start antiretroviral therapy (ART) with high HIV viral load.
FDA Approves Once-Daily Nevirapine
- Details
- Category: Approved HIV Drugs
- Published on Friday, 01 April 2011 00:50
- Written by FDA
The FDA this week approved a new longer-acting formulation of nevirapine (Viramune XR), enabling once-daily dosing. 
FDA Approves NNRTI Rilpivirine (Edurant, TMC278)
- Details
- Category: Approved HIV Drugs
- Published on Friday, 20 May 2011 03:56
- Written by FDA
New NNRTI rilpivirine (brand name Edurant, formerly TMC278) received U.S. Food and Drug Administration (FDA) approval Friday for HIV patients starting first-line therapy.
Once-Daily Elvitegravir Matches Raltegravir in Phase 3 Study
- Details
- Category: Approved HIV Drugs
- Published on Friday, 25 March 2011 01:53
- Written by Gilead Sciences
Experimental integrase inhibitor shown non-inferior to raltegravir (Isentress) for treatment-experienced patients, developer reports.
Web Design and Development by